HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

La Roche-Posay donates sunscreen

This article was originally published in The Rose Sheet

Executive Summary

In honor of National Sun Safety Week, L'Oreal division teams with Skin Cancer Foundation to distribute its Anthelios SX Daily Moisturizing Cream with SPF 15 - formulated with its photostable Memoryl SX technology - to communities across the nation. Missouri health departments in Putnam County and Schuyler County received 100 pieces of the product, while Viejo, Calif. received 400 pieces for a June 6 Relay for Life event benefiting the American Cancer Society, according to June 19 release. Additionally firm sent 300 pieces to Baker & Taylor publishing house in Bridgewater, N.J. for distribution at its Summer Safety event June 11. More than $25,000 worth of product was donated in total, the company says. "By partnering with the Skin Cancer Foundation, we want to show that we are just as committed to education and promotion of skin cancer awareness as we are to the research and development of our products," La Roche-Posay General Manager Yannick Raynaud says. Dr. Perry Robins, president of the Skin Cancer Foundation, states: "The brand echoes our message that daily broad-spectrum protection is of the utmost importance." This is not the first time La Roche-Posay has partnered with the Skin Cancer Foundation to educate consumers (1"The Rose Sheet" June 11, 2007, In Brief)

You may also be interested in...



La Roche-Posay for skin cancer prevention

This month, La Roche-Posay is donating a portion of the proceeds - up to a total of $10,000 - from sales of Anthelios SX Daily Moisturizing Cream with SPF 15 to The Skin Cancer Foundation, according to a June 4 release. "As the makers of a new sun-care product, we felt it was fundamental to support The Skin Care Foundation in their efforts to educate the public about the dangers of skin cancer and the steps that can be taken to help prevent ... the fastest-growing cancer in the U.S.," Yannick Raynaud, VP-marketing and medical detailing, states. Formulated with the Mexoryl SX organic, highly photo-stable sun filter for protection against short UVA waves for long periods of time, Anthelios SX is the first sunscreen formula to be approved by FDA since 1988, La Roche-Posay says (1"The Rose Sheet" May 21, 2007, In Brief)...

Entries Begin To Roll In For 2024 Industry Awards

Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.

‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach

In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel